Hims & Hers Health Inc. Stock News

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. “We are always looking for long-term, sustainable ways to increase access to care for our cus...

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn't the one-sided machine it used to be a few decades ago. Thanks to the flow of information and availability in the digital space, today's market has become more interconnected than ever before.

Hims & Hers (HIMS -5.42%) has put investors on a roller coaster ride in 2025.

Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% year-over-year and operating leverage improving. The business model's shift to a subscription platform with personalized care unlocks significant long-term free cash flow and expansion opportunities. Management's guidance and execution support a path to $6.5B in revenue by 2030, with my valuation...

Hims and Hers, Inc. NYSE: HIMS shows strongly bullish signs that begin and end with the stock price action. It reflects volatility, but the bias is upward with rising support and the most recent swing, a bullish rebound, looks very strong within the pattern.

Hims stock is nearing a trendline entry after earnings gave shares a boost on May 6. The telehealth provider leads the IBD 50.

There's a well-known saying in the investing world, which advises investors to “sell in May and go away.

Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though relian...